Researching teacher learning through self-video by Ingram, J, Coles, A

Defining human T lymphocyte subsets using putative markers derived from mouse sage libraries by Thompson, S, Cobbold, S, Waldmann, H, Coles, A

Encephalitis and schizophrenia: a matter of words reply by Lennox, B, Coles, A, Vincent, A

Antibody-mediated encephalitis: a treatable cause of schizophrenia. by Lennox, B, Coles, A, Vincent, A

Authors' reply by Lennox, B, Coles, A, Vincent, A

ANTI-GAD65, NMDAR AND VGKC ANTIBODIES DETECTED IN FIRST EPISODE PSYCHOSIS by Lennox, B, Zandi, M, Irani, S, Coles, A, Vincent, A

Preventing the immunogenicity of biological therapies by Somerfield, J, Waldmann, H, Compston, D, Hale, G, Coles, A

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. by Moreau, T, Coles, A, Wing, M, Isaacs, J, Hale, G, Waldmann, H, Compston, A

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. by Cox, A, Thompson, SA, Jones, J, Robertson, V, Hale, G, Waldmann, H, Compston, D, Coles, A

Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. by Brown, J, Martin, P, Thorpe, J, Michell, A, Coles, A, Cox, A, Vincent, A, Zandi, MS

Inflammation, demyelination, and axonal degeneration: Three aspects of the pathogenesis of multiple sclerosis revealed by campath-1H treatment by Coles, A, Wing, MG, Molyneux, P, Paolillo, A, Davie, C, Hale, G, Miller, D, Waldmann, H, Compston, A

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. by Coles, A, Wing, MG, Molyneux, P, Paolillo, A, Davie, C, Hale, G, Miller, D, Waldmann, H, Compston, A

Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1) by Lennox, B, Tomei, G, Vincent, S-A, Yeeles, K, Pollard, R, Palmer-Cooper, E, Jones, PB, Zandi, MS, Coles, A

Disease-relevant autoantibodies in first episode schizophrenia. by Zandi, MS, Irani, SR, Lang, B, Waters, P, Jones, P, McKenna, P, Coles, A, Vincent, A, Lennox, B

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. by Coles, A, Wing, M, Smith, S, Coraddu, F, Greer, S, Taylor, C, Weetman, A, Hale, G, Chatterjee, V, Waldmann, H, Compston, A

Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series. by Zandi, MS, Deakin, J, Morris, K, Buckley, C, Jacobson, L, Scoriels, L, Cox, A, Coles, A, Jones, P, Vincent, A, Lennox, B

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. by Coles, A, Cox, A, Le Page, E, Jones, J, Trip, SA, Deans, J, Seaman, S, Miller, D, Hale, G, Waldmann, H, Compston, D

SERUM AUTOANTIBODIES TO GLUTAMIC ACID DECARBOXYLASE ARE ASSOCIATED WITH REDUCED CORTICAL GABA LEVELS IN PATIENTS WITH EPILEPSY by Stagg, C, Lang, B, Hest, J, Cavey, A, Johansen-Berg, H, Coles, A, Hart, Y, Sisodiya, S, Wroe, S, Duncan, J, Vincent, A, Palace, J

CAMPATH-IH in multiple sclerosis. by Moreau, T, Coles, A, Wing, M, Thorpe, J, Miller, D, Moseley, I, Issacs, J, Hale, G, Clayton, D, Scolding, N, Waldmann, H, Compston, A

A novel strategy to reduce the immunogenicity of biological therapies. by Somerfield, J, Hill-Cawthorne, G, Lin, A, Zandi, MS, McCarthy, C, Jones, J, Willcox, M, Shaw, D, Thompson, SA, Compston, A, Hale, G, Waldmann, H, Coles, A